Search

Your search keyword '"Conway, Olivia J"' showing total 26 results

Search Constraints

Start Over You searched for: Author "Conway, Olivia J" Remove constraint Author: "Conway, Olivia J"
26 results on '"Conway, Olivia J"'

Search Results

1. Limited oxygen in standard cell culture alters metabolism and function of differentiated cells

2. Author Correction: Limited oxygen in standard cell culture alters metabolism and function of differentiated cells

3. Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

4. A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

5. Association of ABI3 and PLCG2 missense variants with disease risk and neuropathology in Lewy body disease and progressive supranuclear palsy

6. Limited oxygen availability in standard cell culture alters metabolism and function in terminally-differentiated cells

7. ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans

8. A high-content endogenous GLUT4 trafficking assay reveals new aspects of adipocyte biology

9. Trafficking regulator of GLUT4-1 (TRARG1) is a GSK3 substrate

12. Correction to:A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (Acta Neuropathologica, (2019), 138, 2, (237-250), 10.1007/s00401-019-02026-8)

13. Trafficking regulator of GLUT4-1 (TRARG1) is a GSK3 substrate.

14. Trafficking regulator of GLUT4-1 (TRARG1) is a GSK3 substrate

15. Additional file 1 of Association of ABI3 and PLCG2 missense variants with disease risk and neuropathology in Lewy body disease and progressive supranuclear palsy

16. Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity

17. A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (vol 138, pg 237, 2019)

18. P2-294: RETROSPECTIVE REVIEW OF CLINICAL FEATURES OF ABCA7 LOSS-OF-FUNCTION MUTATION CARRIERS IN LATE-ONSET ALZHEIMER'S DISEASE

19. A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity

20. A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity

21. P1‐160: ABI3 AND PLCG2 AS RISK FACTORS FOR ALZHEIMER'S DISEASE IN CAUCASIANS AND AFRICAN AMERICANS

22. A Nonsynonymous Mutation in PLCG2 Reduces the Risk of Alzheimer's Disease, Dementia with Lewy-Bodies and Frontotemporal Dementia, and Increases the Likelihood of Longevity

25. Phenotypic characterization of Adignull mice suggests roles for adipogenin in the regulation of fat mass accrual and leptin secretion

26. A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity

Catalog

Books, media, physical & digital resources